FABP4 and metabolic dysfunction-associated steatohepatitis: Elevation of A‐FABP in different hepatic cell lineages exerts distinct pathogenic effects and has been implicated in different stages of chronic liver disease.[10, 11, 12, 13] A‐FABP instigates the inflammatory response in Kupffer cells and infiltrated macrophages contributing to NASH and cirrhosis[10, 11] while its elevation in intratumoral HSCs and endothelial cells associates with the development of hepatocellular carcinoma.[12, 35] The present study reveals an increased expression of A‐FABP, especially in the LSECs, in mouse BDL model of liver fibrosis.